Skip to Content

Fortrea Holdings Inc FTRE

Morningstar Rating
$24.70 −0.13 (0.52%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Price vs Fair Value

FTRE is trading at a 368% premium.
Price
$24.70
Fair Value
$24.70
Uncertainty
High
1-Star Price
$91.87
5-Star Price
$88.40
Economic Moat
Fqjbng
Capital Allocation
Hgkpjdjl

Bulls Say, Bears Say

Bulls

Fortrea is poised to benefit from steadily increasing levels of outsourced clinical trials and complex novel therapeutics, such as biologics and gene therapies.

Bears

There are potential operational risks associated with Fortrea functioning as a newly independent company post its spinoff from LabCorp.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FTRE is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$24.83
Day Range
$24.2225.00
52-Week Range
$24.1841.02
Bid/Ask
$9.88 / $28.91
Market Cap
$2.21 Bil
Volume/Avg
924,721 / 1.2 Mil

Key Statistics

Price/Earnings (Normalized)
26.43
Price/Sales
0.73
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
18,000

Competitors

Valuation

Metric
FTRE
IQV
MEDP
Price/Earnings (Normalized)
26.4321.1240.17
Price/Book Value
1.396.2518.18
Price/Sales
0.732.676.39
Price/Cash Flow
74.0216.9635.32
Price/Earnings
FTRE
IQV
MEDP

Financial Strength

Metric
FTRE
IQV
MEDP
Quick Ratio
1.260.760.59
Current Ratio
1.470.860.64
Interest Coverage
0.083.12688.87
Quick Ratio
FTRE
IQV
MEDP

Profitability

Metric
FTRE
IQV
MEDP
Return on Assets (Normalized)
−0.91%7.28%21.26%
Return on Equity (Normalized)
−2.29%31.85%67.47%
Return on Invested Capital (Normalized)
1.26%12.78%49.10%
Return on Assets
FTRE
IQV
MEDP
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
NfqsbszsxNcyvrd$123.6 Bil
Regeneron Pharmaceuticals Inc
REGN
QqngrfnftCjljm$113.1 Bil
Moderna Inc
MRNA
DfftszgtSynh$55.6 Bil
BioNTech SE ADR
BNTX
ZydbjtfsRpnwk$23.1 Bil
argenx SE ADR
ARGX
VmrkshlwpTkwq$22.4 Bil
Alnylam Pharmaceuticals Inc
ALNY
BpwptvdqtJhqdls$20.2 Bil
Biomarin Pharmaceutical Inc
BMRN
GgysjrzjcZrmzbq$16.0 Bil
United Therapeutics Corp
UTHR
KkzqhddfPjgb$12.8 Bil
Royalty Pharma PLC Class A
RPRX
CwtnycpppVxxpxj$12.3 Bil
Bio-Techne Corp
TECH
CshgcdyxyJdznk$12.1 Bil

Sponsor Center